Abstract |
We have studied the interaction of coenzyme Q with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ( MPTP) and its metabolites, 1-methyl-4-phenyl-2,3-dihydropyridinium ( MPDP(+)) and 1-methyl-4-phenylpyridinium (MPP(+)), the real neurotoxin to cause Parkinson's disease. Incubation of MPTP or MPDP(+) with rat brain synaptosomes induced complete reduction of endogenous ubiquinone-9 and ubiquinone-10 to corresponding ubiquinols. The reduction occurred in a time- and MPTP/ MPDP(+) concentration-dependent manner. The reduction of ubiquinone induced by MPDP(+) went much faster than that by MPTP. MPTP did not reduce liposome-trapped ubiquinone-10, but MPDP(+) did. The real toxin MPP(+) did not reduce ubiquinone in either of the systems. The reduction by MPTP but not MPDP(+) was completely prevented by pargyline, a type B monoamine oxidase ( MAO-B) inhibitor, in the synaptosomes. The results indicate that involvement of MAO-B is critical for the reduction of ubiquinone by MPTP but that MPDP(+) is a reductant of ubiquinone per se. It is suggested that ubiquinone could be an electron acceptor from MPDP(+) and promote the conversion from MPDP(+) to MPP(+) in vivo, thus accelerating the neurotoxicity of MPTP.
|
Authors | H Shi, N Noguchi, Y Xu, E Niki |
Journal | FEBS letters
(FEBS Lett)
Vol. 461
Issue 3
Pg. 196-200
(Nov 19 1999)
ISSN: 0014-5793 [Print] England |
PMID | 10567696
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Liposomes
- Neurotoxins
- Pyridinium Compounds
- Ubiquinone
- 1-methyl-4-phenyl-2,3-dihydropyridinium
- Monoamine Oxidase
- Ubiquinone Q2
- ubiquinol
- ubiquinone 9
- 1-Methyl-4-phenylpyridinium
|
Topics |
- 1-Methyl-4-phenylpyridinium
(metabolism)
- Animals
- Biotransformation
- Liposomes
- Male
- Monoamine Oxidase
(metabolism)
- Neurotoxins
(metabolism)
- Oxidation-Reduction
- Pyridinium Compounds
(metabolism)
- Rats
- Rats, Wistar
- Synaptosomes
(drug effects, metabolism)
- Ubiquinone
(analogs & derivatives, metabolism)
|